CAMBRIDGE, Mass.–(BUSINESS WIRE)–#alzheimers—Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company.
Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage oncology company. Prior to Atossa, he was CFO at BioIntelliSense, a commercial stage medtech company focused on remote patient monitoring.
He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of multiple CNS therapeutics assets, and to advance multiple clinical and discovery programs. In addition, Mr. Weaver previously served as CFO of Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), where he led their reverse merger and Nasdaq listing. During his career, Mr. Weaver has managed M&A transactions involving oncology products, medical device technologies, and other biotech assets.
“We are delighted to welcome Greg, who brings decades of expertise leading high-performing teams in the private and public sectors,” said Brent Vaughan, Chief Executive Officer at Cognito Therapeutics. “Greg brings a proven track record of success on both the operating and finance sides of our industry, as we advance our pipeline of disease-modifying therapies for neurodegenerative disorders. He is an experienced CFO with a strong track record of fundraising, raising over $2B in his career including in the CNS industry.”
“I am excited to join Cognito at such a dynamic time. The company is advancing its pivotal HOPE study in Alzheimer’s disease, and I look forward to working with Brent and the rest of the senior management and scientific teams to help bring innovative non-invasive neuromodulation therapies to patients,” said Greg Weaver, CFO, Cognito Therapeutics.
Mr. Weaver has been involved with development programs that led to multiple FDA approvals and product launches. Several of his companies have had successful exits. Mr. Weaver is a Board Member of Rejuveron Life Sciences and BioIntelliSense, and also serves on the non-profit board of HarborPath. He began his career as a CPA with Arthur Andersen.
Cognito’s pivotal study, HOPE Study for Alzheimer’s Disease evaluates a novel wearable device that has the potential to slow the progression of Alzheimer’s disease, without the potential safety concerns associated with medications or highly invasive procedures.
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
Contacts
Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
